Screener
Ligand Pharmaceuticals LGND Royalties — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Revenues and income: | ||||
| Revenue from intangible royalty assets | $37,362 | $30,084 | $70,293 | $51,671 |
| Income from financial royalty assets | 10,670 | 6,313 | 20,697 | 12,215 |
| Royalties | 48,032 | 36,397 | 90,990 | 63,886 |
| Captisol | 7,978 | 8,287 | 16,632 | 21,747 |
| Contract revenue and income | 7,683 | 2,943 | 7,793 | 7,327 |
| Total revenues and income | 63,693 | 47,627 | 115,415 | 92,960 |
| Operating costs and expenses: |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's royalties — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported royalties — total revenues and income of $48.03M in Q2 2026.
- How has Ligand Pharmaceuticals's royalties — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's royalties — total revenues and income increased by 32.0% year-over-year, from $36.4M to $48.03M.
- What is the long-term trend for Ligand Pharmaceuticals's royalties — total revenues and income?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's royalties — total revenues and income has grown at a 34.7% compound annual growth rate (CAGR), from $48.93M to $161M.
- What does royalties — total revenues and income mean?
- This metric represents the aggregate financial inflow generated by the royalties segment, encompassing both direct product royalties and associated milestone or licensing income. It serves as a comprehensive measure of the total economic value captured from the company's portfolio of licensed pharmaceutical assets. Tracking this figure allows investors to assess the overall performance and monetization success of the company's intellectual property partnerships.
Ask your AI about Ligand Pharmaceuticals's royalties — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude